“…We observed a clinical effect in herpes zoster [10] and we gave IFN as a shield against infections in leukemic children with encouraging results [24].…”
“…We observed a clinical effect in herpes zoster [10] and we gave IFN as a shield against infections in leukemic children with encouraging results [24].…”
“…Clinical activity of IFN-a in AML Clinical attempts to use IFN-a in the treatment of AML were already made in the mid-1960s and in the early 1970s (Falcoff et al 68 ; Ahstrom et al 69 ). While these pioneer studies did not allow to draw direct conclusions on its therapeutic value, the first evidence of in vivo antileukemic activity was provided by Hill et al in 1979.…”
Section: Clinical Experience With Ifn-a In Amlmentioning
confidence: 99%
“…Early studies of low-dose IFN-a failed to objectively demonstrate antileukemic responses, 69,74 the first clinical success was achieved after high-dose continuous intravenous administration of IFN-a 10 ( Table 2). Although some reports have suggested that low-dose IFN-a might be effective in AML, 75 the majority of the studies have indicated an association between IFN-a dosage and therapeutic efficacy.…”
Section: Heterogeneity In Clinical Outcomementioning
Interferon-a (IFN-a), a type I IFN, is a well-known antitumoral agent. The investigation of its clinical properties in acute myeloid leukemia (AML) has been prompted by its pleiotropic antiproliferative and immune effects. So far, integration of IFN-a in the therapeutic arsenal against AML has been modest in view of the divergent results of clinical trials. Recent insights into the key pharmacokinetic determinants of the clinical efficacy of IFN along with advances in its pharmaceutical formulation, have sparked renewed interest in its use. This paper reviews the possible applicability of IFN-a in the treatment of AML and provides a rational basis to re-explore its efficacy in clinical trials.
“…Our data as well as those reported in the literature (20,23) indicate that these effects were reduced or eliminated by alternative purification methods, suggesting that they were due to impurities. Febrile reactions have also been noted in patients with L-interferon (1,14,15,17,19,24). However, a recent preparation of purified L-interferon was not pyrogenic in a patient who showed a febrile response to F-interferon.…”
Section: Serum Titers Of Interferon In Humansmentioning
Human fibroblast interferon (F-interferon) purified by adsorption on controlled-pore glass was given intramuscularly to patients at daily dosages of up to 20 x 106 units. Serum levels of antiviral activity were low or undetectable. In contrast, reasonably high serum titers were found in patients receiving interferon prepared from leukocytes (L-interferon). Similarly, in rabbits lower serum titers were seen with F-interferon than with L-interferon. These results are at variance with those obtained earlier
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.